These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 1661607

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG.
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W.
    Transplantation; 2007 Feb 27; 83(4):433-8. PubMed ID: 17318076
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC, Curtis JL, Szmuszkovicz JR, Horn MV, Ford HR, Woo MS, Wang KS.
    J Pediatr Surg; 2008 Dec 27; 43(12):2174-7. PubMed ID: 19040929
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression.
    Olivari MT, Diekmann RA, Kubo SH, Braunlin E, Jamieson SW, Ring WS.
    J Heart Transplant; 1990 Dec 27; 9(6):618-21. PubMed ID: 2277297
    [Abstract] [Full Text] [Related]

  • 11. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs.
    Haematologica; 2002 Jan 27; 87(1):67-77. PubMed ID: 11801467
    [Abstract] [Full Text] [Related]

  • 12. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
    Burra P, Buda A, Livi U, Rigotti P, Zanus G, Calabrese F, Caforio A, Menin C, Canova D, Farinati F, Luciana Aversa SM.
    Eur J Gastroenterol Hepatol; 2006 Oct 27; 18(10):1065-70. PubMed ID: 16957512
    [Abstract] [Full Text] [Related]

  • 13. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A, Jiménez L, Aranda I, Alvarez L, González M, Rocamora N, Olivares J.
    Nefrologia; 2002 Oct 27; 22(5):463-9. PubMed ID: 12497748
    [Abstract] [Full Text] [Related]

  • 14. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb 27; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML, Swinnen LJ, Plaisance KT, Schnell C, Grogan TM, Schneider BG, Southwest Oncology Group.
    Transplantation; 2003 Sep 27; 76(6):959-64. PubMed ID: 14508361
    [Abstract] [Full Text] [Related]

  • 17. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases.
    Wood BL, Sabath D, Broudy VC, Raghu G.
    Cancer; 1996 Nov 15; 78(10):2223-8. PubMed ID: 8918418
    [Abstract] [Full Text] [Related]

  • 18. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection.
    Ahya VN, Douglas LP, Andreadis C, Arnoldi S, Svoboda J, Kotloff RM, Hadjiliadis D, Sager JS, Woo YJ, Pochettino A, Schuster SJ, Stadtmauer EA, Tsai DE.
    J Heart Lung Transplant; 2007 Aug 15; 26(8):839-44. PubMed ID: 17692789
    [Abstract] [Full Text] [Related]

  • 19. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
    Ben-Ari Z, Amlot P, Lachmanan SR, Tur-Kaspa R, Rolles K, Burroughs AK.
    Liver Transpl Surg; 1999 May 15; 5(3):184-91. PubMed ID: 10226108
    [Abstract] [Full Text] [Related]

  • 20. Quantitative analysis of immunosuppression in cyclosporine-treated heart transplant patients with lymphoma.
    Brumbaugh J, Baldwin JC, Stinson EB, Oyer PE, Jamieson SW, Bieber CP, Henle W, Shumway NE.
    J Heart Transplant; 1985 May 15; 4(3):307-11. PubMed ID: 3039097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.